Travel Medicine and Infectious Disease
Volume 8, Issue 1 , Pages 47-50 , January 2010

Quadrivalent meningococcal vaccines: Hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine

Received 23 July 2009 ,Revised 7 December 2009 ,Accepted 9 December 2009.

References 

  1. Ericson L, De Wals P. Complication and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Clin Infect Dis. 1998;26:1159–1164
  2. Harrison LH, Trotter CL, Ramsey ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl. 2):B51–B63
  3. LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 2009;27(Suppl. 2):B13–B19
  4. Wilder-Smith A. Meningococcal disease: risk for international travellers and vaccine strategies. Travel Med Infect Dis. 2008;6:182–186
  5. Harrison IH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19:142–164
  6. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009;275:830–841
  7. Østergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Imunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25years. Vaccine. 2009;27:161–168
  8. Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J. 2007;26:716–722
  9. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159:907–913
  10. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest. 1975;56:1536–1547
  11. MacDonald N, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunological memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers. J Am Assoc Am. 1998;280:1685–1689
  12. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces hyporesponsiveness in adults that is overcome by conjugate vaccine. J Infect Dis. 2000;181:761–764
  13. Southern J, Deane S, Ashton L, et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol. 2004;11:1100–1104
  14. MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine?. J Am Med Assoc. 2000;283:1826–1827
  15. Trotter CL, McVernon J, Ramsey ME. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine. 2008;26:4434–4445
  16. Bröker M. Vaccination against meningococcal disease: which vaccine to use?. J Travel Med. 2002;9:168–169
  17. MacLennan J, Obaro S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine. 1999;17:3086–3093
  18. Borrow R, Joseph H, Andrews N, et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine. 2001;19:1129–1132
  19. Jokhdar H, Borrow R, Sultan A, et al. Immunologic hyporesponsiveness to serogroup C but not to serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Imunol. 2004;11:83–88
  20. Gold R, Lepow ML, Goldschneider I, Draper T, Gotschlich EC. Kinetics of antibody production to group A an group C meningococcal polysaccharide vaccine administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis. 1979;140:690–697
  21. Käyhty H, Karanko V, Peltola H, Sarna S, Mäkelä H. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Clin Infect Dis. 1980;142:861–868
  22. Nathan N, Rose AMC, Legros D, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis. 2007;13:920–923
  23. Al Mazrou Y, Khalil M, Borrow R, et al. Serologic response to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5years of age. Infect Immun. 2005;73:2932–2939
  24. Al-Mazriou Y, Khalil M, Bravo C et al. Meningococcal conjugate vs meningococal polysaccharide vaccine in Saudi Arabian adolescents previously vaccinated with multiple doses of meningococcal polysaccharide vaccine. Abstract O002. 10th Meeting of the European Monitoring Group for Meningococci (EMGM), Manchester, UK, June 17–19, 2009.
  25. Khalil M, Al-Mazrou Y, Bravo C et al. Response to quadrivalent meningococcal conjugate vaccine in Saudi Arabian children who previously received 2 doses of quadrivalent meningococcal polysaccharide vaccine before 1years of age. Abstract P008. 10th Meeting of the European Monitoring Group for Meningococci (EMGM), Manchester, UK, June 17–19, 2009.

PII: S1477-8939(09)00179-3

doi: 10.1016/j.tmaid.2009.12.001

Travel Medicine and Infectious Disease
Volume 8, Issue 1 , Pages 47-50 , January 2010

Article Tools

* Image Usage & Resolution